CD79A and infection: Consistent with this, very recent studies have analyzed the ability of anti-SARS-CoV-2 vaccines to boost the mucosal immune response, showing that vaccination can elicit mucosal IgA responses and neutralize IgA at the oral level, which is detectable for over 5 months after vaccination and is enhanced by a subsequent breakthrough infection by SARS-CoV-2 [23,24].